Introduction
Non-islet cell tumor is, next to insulinoma, the second most frequent cause of fasting hypoglycemia in Japan ( 1 ). Recently, insulin-like growth factor (IGF)-II has been reported to have some causal role in non-islet cell tumor hypoglycemia (NICTH) (2-5). It has also been pointed out that molecular size heterogeneity of IGF-II exists in tissues or in sera of patients with NICTH (6-9). The exact mechanisms of why and how the tumor produces various sizes of IGF-II and which of these account(s) for the hypoglycemia are not well clarified. We examined a case ofhepatocellular carcinoma (HCC) associated with frequent hypoglycemic attacks. We demonstrated elevation of the serum IGF-II/IGF-I ratio, a decreased level of authentic IGF-II in contrast to existence of high molecular weight form ofIGF-II (big IGF-II) in sera, and re-expression of fetal IGF-II mRNA in the tumor tissue. These findings indicate that big IGF-II might be responsible for the hypoglycemia. To the best of our knowledge, this is the first reported case of NICTH in big IGF-II producing HCC that has been proved to be associated with HCV infection.
Case Report
A 76-year-old Japanese woman was admitted to the Omiya Medical Center, Jichi Medical School on June 18, 1993, because she had suffered from frequent hypoglycemic attacks for the previous two weeks. She had a history of post-transfusional hepatitis following hysterectomy for myoma uteri at age 44, and was shown to be positive for hepatitis C virus antibody at the age of 71. There was no family history of diabetes mellitus or chronic liver disease. The patient had been followed for liver cirrhosis since 1991. An HCC was detected inFebruary 1992 by ultrasound examination. Transcatheter intra-arterial chemotherapy was carried out three times (March and September 1 992 and January 1993). These treatments did not result in any reduction in the size of the tumor, which grew rapidly, diffusely invading the entire liver. The patient suffered from jaundice, ascites, and pleural effusion since June 1993. Frequent attacks of drowsiness and confusion early in the morning also appeared. On every occasion, the plasma glucose level was low (<30 mg/dl) and she was successfully treated by intravenous administration of glucose. Figure 1 . The computed tomogram with contrast medium shows: (a) a huge hepatic mass that involves the entire liver and the portal vein, which is of relatively low density and is irregularly enhanced, (b) a tumor embolus within the inferior vena cava.
(AFP) level over 30,000 ng/ml (normal <20). Anti-hepatitis C virus antibody (HCVAb) was positive, hepatitis B surface antigen (HBsAg) and antibody (HBsAb) were negative. A computed tomogram of the abdomen demonstrated a huge liver t umor and marked splenomegaly ( Fig. 1 ). Endocrine and metabolic data are shown in Table 1 . Daily profile of PG revealed hyperglycemia at night and hypoglycemia at dawn. Plasma samples obtained when disorientation and confusion were present showed both the PG concentration and immunoreactive insulin (IRI) level to be low, and a IRI/PG ratio of less than 0. 1. C-peptide immunoreactivity (CPR) in the urine over three consecutive days was low (ranging within 4.3-17.0 jig/day, normal 50-120).
Serum fasting glucagon level was elevated to 229 pg/ml. Glucagon challenge test (1 mg intravenous) resulted in poor response of PG, IRI, and CPR. From these data, insulin-related hypoglycemia was ruled out. Accordingly we evaluated the serum insulin-like substances.
Serum IGF-I level was extremely low in comparison
to IGF-II level which was within the normal range, and the IGF-II/IGF-I ratio was consequently elevated to up to 21 (normal 1.7-7. 1). Western blot analysis of serum IGF-II (10) disclosed a decrease At autopsy the liver contained multiple nodular tumors of various sizes (Fig. 3 ). Normal hepatic tissue or even cirrhotic tissue was difficult to recognize macroscopically.
The tumor was histologically diagnosed as an Edmondson grade III hepatocellular carcinoma (Fig. 4) Western blot analysis of serum IGF-II was performed in a small number of patients with various stages of liver damage due to HCV infection to investigate the relationship between the presence of big IGF-II and hepatic tumorigenesis ( Fig. 6 ). Among 2 carriers, 2 patients with chronic persistent hepatitis, 6 with chronic active hepatitis, 1 with liver cirrhosis, and 4 with HCC, wefound one patient with HCC who showed the presence of serum big IGF-II.
Discussion
In 1981, Daughaday et al (2) reported that plasma IGF-II, known to accelerate fetal tissue development and to exhibit insulin-like metabolic effects, was elevated in a case with NICTH. HumanIGF-II is a polypeptide consisting of 67 amino acids, with amolecular weight of7.5 kDa, and its gene is located on the short arm of chromosome 1 1 (1 Ipl5).
IGF-II originates from the precursor, preproIGF-II, which possesses an additional signal peptide (24 amino acids) and a carboxyl-terminal extension called the E-domain (89 amino acids). By posttranslational proteolytic process, preproIGF-II has its signal peptide removed initially to be proIGF-II, and then the E- Recently, Zierath et al (13) demonstrated that free IGF-II stimulates human skeletal muscle glucose transport at physiological concentrations in a dose-dependent manner, although it is 20 times less potent than insulin on a molar basis and has about three quarters of the potency of IGF-I (14). The IGFBPs appear to play counter-regulating role in IGF-II-stimulated glucose transport.
Cariani et al (15) suggested an IGF-IImediated autocrine mechanism of growth regulation in HCC, because a marked increase in IGF-II 'mRNA was detected in tumor cells and NICTH lacks feedback inhibition of IGF-II in spite of hypoglycemic condition. The comparative mitogenic potencies of IGF-II, insulin and IGF-I have not yet been well clarified. It is feasible, therefore, that IGF-II itself has been considered responsible for NICTH. While a causative role of IGF-II in NICTH has long been suspected, efforts to demonstrate an increased concentration of IGF-II in serum have yielded inconsistent results. Daughaday et al (2) showed by radioreceptor assay that 1 0 of 14 sera from patients with NICTH had elevations of IGF-II, but for the most part the elevations were so small that they did not appear sufficient to explain the development ofNICTH. Furthermore, several reported cases of NICTH did not show any correlation between hypoglycemia and serum immunoreactive IGF-II levels, not to mention that both IGF-I and insulin levels were low (16). The case presented here also did not exhibit any correlation between the total IGF-II level and hypoglycemia. Therefore, it was difficult to satisfactorily explain NICTH based on authentic IGF-II alone.
In 1988, Daughaday et al (7) detected high molecular weight IGF-II (big IGF-II) in the serum of a patient with leiomyosarcoma and hypoglycemia despite a normal serum IGF-II concentration. In addition, Zapf et al (8) found that, in 25 out of 28 patients with NICTH, serum immunoreactive IGF-II levels were decreased in contrast to the increase in big IGF-II levels. Thus the finding that big IGF-II comprised the major fraction of the serum IGF-II in the present patient is in good agreement with these reports. Furthermore, the insulin-like activities of partially purified big IGF-II in stimulating glucose metabolism in rat fat cells was two-to three-fold higher than authentic IGF-II on a molecular basis (8). Since serum IGF-I levels were low and the IGF-II/IGF-I ratio was high, the patient met the diagnostic criteria of NICTH proposed by Teale and Marks (3). Low serum IGF-I level in NICTH is considered to be caused by feedback inhibition of both growth hormone (4, 7) and insulin ( 17). Therefore, these data suggest that the hypoglycemia in the present patient might have been due to circulating big, rather than authentic , IGF-II. The big IGF-II molecule consists of incompletely processed or unprocessed proIGF-II with various portions of the Edomain ( 1 8). Furthermore, the variety of molecular sizes found in serum and in tissue is thought to be in part due to attachment of various chains ofoligosaccharide. In the present case, the big IGF-II fraction in serum was heterogeneous in size ranging from 13.7 kDa to 23 kDa by Western blotting. The molecular heterogeneity of big IGF-II in this patient may reflect complexity of processing of proteins in tumor tissue.
Various sizes ofIGF-II mRNA have been detected in tissues from healthy controls. Among these, one that is 5.3 kb in size and known as the "adult type" is a transcript specific to adult liver tissue, whereas, another 6.0 kb in size and of the "fetal type" is expressed widely in fetal tissues as well as in adult tissues other than liver (19, 20) . Tumor tissues of NICTH contain various sizes ofIGF-II mRNA, however the presence of the 6.0 kb mRNA has been specifically implicated to represent carcinogenesis (14). Cariani et al (21) \\\^^^\\^^F igure 6. Western immunoblot analysis of serum IGF-II in patients with various stages of HCV infection using the same procedure as that in Fig. 2 . IGF-II: recombinant human IGF-II, Normal: normal control, Carrier: asymptomatic carrier, CPH: chronic persistent hepatitis, CAH: chronic active hepatitis, LC: liver cirrhosis, HCC: hepatocellular carcinoma. Big IGF-II is clearly detectable in one of four HCC patients (middle band in the lower right panel). The extra bands at~15 kDa seen in Normal and CAH adjacent to the HCC with big IGF-II are considered to be either IGF-II dimer, which is occasionally detected in normal serum at acidic pH (8), or partially processed proIGF-II amounting 10-20% of the total IGF-II fraction in normal serum (26, 27). transcripts are detected more frequently than AFP mRNAin highly differentiated liver cancers and in the surrounding cirrhotic tissues due to hepatitis B virus (HBV). They concluded that re-expression of fetal IGF-II mRNAmight be a marker of early steps of liver carcinogenesis.
Since 6.0 kb mRNA was included among the three transcripts identified in the present case, it might be a unique index of liver carcinogenesis due to not only HBV but also HCV infection. The possibilities of 6.0 kb IGF-II mRNAhaving significant roles in the development and growth of HCC and the role of HCV infection on IGF-II gene transcription also must be considered. Further study on the copy numbers of the tumor IGF-II gene or its loss of heterogeneity should be undertaken, because the IGF-II gene is known to be imprinted in fetal liver whereas biallelic expression occurs in adult liver, and loss or relaxation of genomic imprinting has been proposed as an epigenetic mechanism for oncogenesis in a variety of human tumors (22) .
Although the relationship between tissue 6.0 kb mRNAand serum big IGF-II has not been understood thoroughly, the presence or absence of big IGF-II in sera from patients with various clinical stages of HCV infection might be a point of interest. Our preliminary data showed that one of four patients with HCC had circulating big IGF-II, though she did not have documented hypoglycemia.
The fasting plasma glucose was 90 mg/dl, and serum IGF-II level was 378 ng/ml. Both authentic IGF-II and big IGF-II were elevated, while IGF-I level was suppressed (<22 ng/ml).
A prolonged fast could not be done 
